With Timetable In Hand And Icahn On Board, Bausch Health Looks To ‘Expedite Spin-Off’

Executives say Bausch + Lomb spin-out preparations will be completed by the end of Q3. When asked, they elaborated on Carl Icahn’s acquisition of 27.8m shares, for a 7.8% stake, and expansion of the firm’s board by two seats for Icahn’s representatives.